SCHEMBL21044009

SCHEMBL21044009

COC(=O)C(C)(C)c1csc(NS(=O)(=O)C(C)(C)C)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTPS1 P17812 3/20 0.44
KMT2A Q03164 5/20 0.42
MEN1 O00255 4/20 0.42
CTPS2 Q9NRF8 2/20 0.40
MAPK1 P28482 3/20 0.38
ATAD2 Q6PL18 1/20 0.37
ALDH1A1 P00352 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HPGD P15428 2/20 0.37
PKM P14618 1/20 0.37
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
POLB P06746 3/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
LMNA P02545 3/20 0.36
MAPT P10636 2/20 0.36
RECQL P46063 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21044012 0.89 KMT2A (0.46) CTPS1KMT2AMEN1CTPS2MAPK1
SCHEMBL22869127 0.87 KMT2A (0.43) CTPS1KMT2AMEN1CTPS2MAPK1
SCHEMBL21076799 0.86 CTPS1 (0.46) CTPS1KMT2AMEN1CTPS2MAPK1
SCHEMBL22869126 0.85 CTPS1 (0.44) CTPS1KMT2AMEN1CTPS2MAPK1
SCHEMBL21044168 0.84 CTPS1 (0.43) CTPS1KMT2AMEN1CTPS2MAPK1
SCHEMBL22869171 0.83 KMT2A (0.41) CTPS1KMT2AMEN1CTPS2MAPK1
SCHEMBL21044015 0.82 CTPS1 (0.58) CTPS1KMT2AMEN1CTPS2ATAD2
SCHEMBL21044395 0.81 CTPS1 (0.39) CTPS1KMT2AMEN1CTPS2MAPK1
SCHEMBL21044083 0.81 CTPS1 (0.39) CTPS1KMT2AMEN1CTPS2MAPK1
SCHEMBL22869109 0.80 CTPS1 (0.54) CTPS1KMT2AMEN1CTPS2ATAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717459-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 EP disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-20210002269-A1 COMPOUNDS STEP PHARMA S.A.S. (FR) 2021-01-07 US disclosed
EP-3492454-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2019-06-05 EP disclosed
EP-3492454-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2019-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 CTPS1 1/4885KMT2A 4442/4885MEN1 4301/4885
US-20210002269-A1 COMPOUNDS UGT1A1, CYP1A1, CYP19A1 CTPS1 2385/4885KMT2A 4127/4885MEN1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.